Oxirane

Oxirane

SCHEMBL4440182

C1CO1.COCc1ccc(O)cc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.46
ESR1 P03372 4/20 0.45
CALM1 P0DP23 1/20 0.42
ESR2 Q92731 2/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ABAT P80404 1/20 0.39
APP P05067 1/20 0.38
CA2 P00918 1/20 0.38
TAAR1 Q96RJ0 2/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
SLC6A2 P23975 1/20 0.38
ERN1 O75460 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63724 0.89 IDO1 (0.56) IDO1ESR1CALM1ESR2MEN1
SCHEMBL26264321 0.82 ESR2 (0.54) IDO1ESR1CALM1ESR2MEN1
Methyl Alcohol SCHEMBL28236652 0.78 IDO1 (0.42) IDO1CALM1APPLMNATP53
SCHEMBL134443 0.78 IDO1 (0.46) IDO1APPLMNATP53ERN1
SCHEMBL27881161 0.77 APP (0.66) CALM1MEN1KMT2AAPPLMNA
SCHEMBL9856466 0.77 APP (0.54) ESR1MEN1KMT2AAPPCA2
SCHEMBL28143197 0.77 APP (0.66) CALM1MEN1KMT2AAPPLMNA
SCHEMBL9856469 0.77 APP (0.54) ESR1MEN1KMT2AAPPCA2
Oxirane SCHEMBL4884714 0.77 ESR1 (0.74) IDO1ESR1ESR2MEN1KMT2A
Hydroquinone SCHEMBL2867425 0.75 ALOX15 (0.61) ESR1ESR2MEN1KMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2129758-A2 PERFUME COMPOSITIONS Givaudan Nederland Services B.V. (NL) 2009-12-09 EP claimed
WO-2008104352-A2 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-09-04 WO claimed
US-9585826-B2 Triggerable compositions for two-stage, controlled release of active chemistry KIMBERLY-CLARK WORLDWIDE, INC. (US) 2017-03-07 US disclosed
US-20140128827-A1 TRIGGERABLE COMPOSITIONS FOR TWO-STAGE, CONTROLLED RELEASE OF ACTIVE CHEMISTRY KIMBERLY-CLARK WORLDWIDE, INC. (US) 2014-05-08 US disclosed
EP-2129758-A2 PERFUME COMPOSITIONS Givaudan Nederland Services B.V. (NL) 2009-12-09 EP disclosed
WO-2008104352-A2 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128827-A1 TRIGGERABLE COMPOSITIONS FOR TWO-STAGE, CONTROLLED RELEASE OF ACTIVE CHEMISTRY BCHE, CEL, ACHE IDO1 701/4885ESR1 1869/4885CALM1 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.